A slew of new offerings made their debut! Reporters from Guangzhou Daily’s New Flower City App found that local Guangzhou pharmaceutical firms showcased their latest research outcomes and integrated medical solutions at this year’s expo.

Guangzhou Baiyunshan Pharmaceutical Holdings Hosts Themed Forum on High-quality Development of Innovative Biomedical Technologies

At the expo, Guangzhou Baiyunshan led more than a dozen subsidiaries to exhibit collectively and hosted the themed event High-quality Development of Innovative Biomedical Technologies. Participating affiliates included Zhongyi, Qixing, Wanglaoji Pharmaceutical, Xingqun, Chenliji, He Jigong and other well-known brands, presenting a full lineup of time-honored TCM preparations and premium wellness products. These formulations embody centuries of Lingnan TCM wisdom, drawing crowds of attendees to consult and experience the products on site.

The expo featured 24 special conferences and forums covering core sectors such as international medical innovation, cutting-edge biomedical technologies, digital intelligent healthcare, brain-computer interfaces, radiopharmaceutical breakthroughs, and the inheritance & innovation of traditional Chinese medicine. On August 22, Guangzhou Pharmaceutical Group co-hosted the themed biomedical technology event with the Women and Children’s Medical Center Affiliated to Guangzhou Medical University.

As a Fortune Global 500 enterprise and the core industry chain leader of Guangdong’s biomedicine and health sector, Guangzhou Pharmaceutical Group has always upheld the cultural roots of TCM. Its participation and forum hosting not only demonstrate the group’s comprehensive layout and strength across the full pharmaceutical & healthcare industrial chain, but also create a high-end platform for in-depth exchanges with domestic and global peers to advance the modernization and internationalization of TCM.

Guangzhou Pharmaceutical Holdings Presents Eight Core Business Segments

On the first day of the expo, Cheng Zhen, President of Guangzhou Pharmaceutical Co., Ltd., a leading South China pharmaceutical distributor, briefed visiting officials on the company’s core business layout, focusing on its industrial layout, real-world implementation cases and future development plans for the Hong Kong & Macao Drug & Device Access Scheme and full-chain radiopharmaceutical services.

A landmark launch took place that day: the country’s first domestic rollout ceremony for lutetium (¹⁷⁷Lu) oxodotreotide and its calibration standard under the Hong Kong & Macao Drug & Device Access Scheme. On August 20, the first full clinical procedure using the calibration standard of this radiopharmaceutical was completed at the First Affiliated Hospital of Jinan University, filling gaps in precision treatment for neuroendocrine tumors in China and delivering a novel, efficient international therapeutic option for patients. Guangzhou Pharmaceutical exclusively provides end-to-end services including import coordination, professional cold-chain logistics and terminal distribution for the product, fully demonstrating its specialized supply chain capacity for premium new and specialty medicines.

The group showcased eight core business capabilities at the expo:

1. Radiopharmaceuticals: closed-loop services covering import, warehousing and clinical delivery

2. International business: dual-port linkage enabling two-way flow of imported medical products and exported innovative therapies

3. HK-Macao Drug & Device Access: one-stop full-cycle landing support

4. Retail pharmacies: integrated online-offline operations

5. E-commerce retail: brand operation and cross-border distribution

6. Medical supply chains: over 100 completed projects for intelligent pharmacies, SPD (Supply-Processing-Distribution) systems and infusion centers

7. Distribution: nationwide channel network coverage

8. Smart logistics: digitalized systems empowering professional pharmaceutical warehousing and delivery

Yipinhong Pharmaceutical Debuts Exclusive Proprietary Products & Translational Innovation Outcomes

Representing Guangzhou’s innovative biopharmaceutical enterprises, Yipinhong Pharmaceutical Group exhibited its core pipeline candidate pozdeutinurad (AR882), an innovative oral gout drug, alongside multiple proprietary chronic disease therapies and specialized pediatric medicines, fully displaying the group’s breakthroughs in pediatric and chronic disease treatment tracks.

The pipeline gout drug pozdeutinurad (AR882) drew intense attention from professional visitors. It is the world’s only oral small-molecule drug proven clinically to dissolve tophi. Positive top-line results from its global multicenter Phase III REDUCE 2 trial have been released, with full data from global and Chinese pivotal Phase III studies slated for disclosure within the year, poised to deliver a revolutionary non-surgical treatment option for patients with tophi worldwide.

The booth also featured Yipinhong’s full portfolio of innovative chronic and pediatric therapies: chronic disease formulations including amlodipine besylate dry suspension (Class 2.2 new domestic drug) and fenofibrate choline sustained-release capsules included in the national medical insurance negotiation catalog; protected TCM pediatric preparations such as Qinxiang Qingjie Oral Liquid and Fuganlin Oral Liquid.

Newman Medical Accelerates Full-scenario Integration of Sports and Healthcare

Newman Medical unveiled its cardiopulmonary fitness-oriented precision sports health integrated solution at the expo, presenting real-world application results across five major scenarios. Concurrent with the exhibition, the 2026 Precision Sports Health Ecosystem Special Forum, co-sponsored by the Guangdong Association for High-quality Biomedical Industry Development and Zhong Nanshan Medical Foundation and hosted by Newman Medical, was held. Experts from medical, research, community health and wellness industries held in-depth discussions on cardiopulmonary fitness assessment, grassroots deployment of exercise prescriptions, and community chronic disease management.

Speakers emphasized that standardized rollout of exercise rehabilitation requires standardized assessment frameworks and actionable community intervention pathways to build closed-loop management covering screening, evaluation, intervention and follow-up, bringing high-quality sports health resources to grassroots communities.

As the forum host, Newman Medical showcased its proprietary “1+3+5+N” precision sports health capability framework, with full-chain service cases spanning hospitals, communities, workplaces, households and regional collaborative hubs, offering replicable models for large-scale sports-health integration. Industry insiders noted the company’s sustained focus on cardiopulmonary fitness, iterative technology upgrades, optimized service systems and joint formulation of industry standards will strongly boost sports-health integration and upgrade chronic disease prevention and the broader wellness industry.

Innogen Pharmaceutical Highlights Metabolic Innovation Rooted in Real Clinical Needs

GLP‑1-based innovative therapies have expanded the boundaries of metabolic disease management in recent years, shifting treatment targets from simple glycemic control to weight management, body composition improvement and long-term metabolic benefits. At the expo, Innogen Pharmaceutical featured its flagship product Efsubaglutide Alfa, presenting its R&D and industrialization progress targeting major metabolic disorders including diabetes and obesity.

Efsubaglutide Alfa has been listed in the National Medical Insurance Drug List, while the company accelerates global expansion. The product recently obtained PIC/S GMP certification in Brazil, expediting registration, market access and commercialization in Brazil and other emerging markets adopting PIC/S GMP standards. Innogen stated it will continue expanding the global footprint of Efsubaglutide Alfa, addressing worldwide unmet clinical needs for metabolic disease treatment with homegrown innovation.

Yike Biotech & Yimi Life Sciences Build a Clinical Data-Driven Full-chain Intelligent Innovative Drug Development Platform

Guangzhou Yike Biotechnology Co., Ltd. and Guangdong Yimi Life Science Research Co., Ltd. showcased their collaborative platform at the expo, centering on real frontline clinical demands to resolve bottlenecks in R&D, translation and innovation through specialized division of labor built on complementary core strengths:

• Yike Biotech focuses on mining and sorting clinical demands, intelligent new drug discovery and full-process experimental verification

• Yimi Life Sciences specializes in pilot process development, intellectual property layout & operation, and industrial resource matchmaking

Original clinical-derived therapeutic concepts are refined into viable translational candidates and sustained drug development pipelines via standardized data aggregation, multi-layer scientific experimental validation and systematic industrial value assessment.

Source: Guangzhou Daily